TFS Capital’s Aimmune Therapeutics AIMT Stock Holding History

TFS Capital’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-23,302	Closed	-$316K	–	1265
2016 Q1	$316K	Buy	+23,302	New	+$364K	0.05%	628

Other funds holding AIMT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TFS Capital's AIMT Position: Q2 2016 in Review

TFS Capital sold out of Aimmune Therapeutics (AIMT) in Q2 2016, closing a stake of 23,302 shares — an estimated $316K sold.

TFS Capital first reported a position in AIMT in Q1 2016 and held it in 1 quarter. The position peaked at $316K in Q1 2016. 74 funds tracked by Wall St. Rank hold AIMT as of Q2 2016.

TFS Capital reported no remaining Aimmune Therapeutics position as of Q2 2016 after selling out during the quarter.
TFS Capital sold 23,302 Aimmune Therapeutics shares in Q2 2016, an estimated $316K.
TFS Capital first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 1 quarter.
TFS Capital's Aimmune Therapeutics position peaked at $316K in Q1 2016.
74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.